There’s very little payer involvement or engagement, the vaccine business, it’s generally good medicine and seen as being, it’s welcomed by pairs typically. So we have not seen any pushback as relates to the recommendation from a payer or pricing perspective. So and I don’t, we don’t expect that would have any impact on the ability for the market to grow, that really comes down to physician recommendations and patient acceptance. But as it relates to the operational changes within the field team and the marketing — sorry the retail segment, I turn it over to Donn.
Donn Casale: Yes. Hey, Jon. So yes, regarding the optimizing of sales force, optimization to sales force, mainly as it relates specifically to retail, as I mentioned, on the call, the targets will be around not only headquarters, which is where we’ve been quite a bit for, for quite some time, establishing relationships that allows us to deploy marketing initiatives, but also engaging at the regional the divisional and the district levels of these retail chains, which is so critical to pull through initiatives and education, whatever it may be to increase identification and recommendation of hepatitis B vaccine. So the whole point there is to really engage the retailer at those different levels. And that’s part of this process, ensuring we have the right sales force attack to allow us to drive forward recommendations throughout the top change.
At the same time within the hospital segment, IDN segment, we’ve gone to a more vertical structure allows account executives to own the decision makers at the top as well as pull through at the clinic level to drive the recommendation. So we feel really good about where we’re at. And a lot of it’s based upon a lot of the learnings we’ve been able to gather over the last several years in launching FSFE.
Jonathan Miller: Great. That that makes sense. Maybe on the Tdap program, do you have any more color on that challenge study that you’re planning on starting by the end of the year. How big it’s going to be and how that will support further development of that program.
Ryan Spencer: We haven’t commented on actual size just yet. But as far as the — how it fits into the whole picture, obviously, demonstrating that the product can be protective in humans is critical. And it’ll allow us to then have a immunogenicity endpoint that we can use to bridge back to in larger studies. So this is a an initial challenge study, It’s likely and expected that we would have to do larger challenge study. In addition to this, this one as part of a longer term development plan, it’s important to also recognize this is a new study design that hasn’t really been done before with a vaccine pertussis. So we’re working with an investigator now to help support his development of a challenge model where we can use a vaccine and allows disease to progress to identify and test efficacy in humans. And so, this pilot study is important on a number of fronts. One for our product, and also to establish the Model
Jonathan Miller: Makes sense. Thanks so much.
Ryan Spencer: Definitely. Thank you for the question.
Operator: Thank you. And we have no further questions at this time. I would like to hand the conference back over to Mr. Ryan Spencer, Chief Executive Officer for closing remarks. You may begin.
Ryan Spencer: Thank you, operator, and thank you all for joining us today. We appreciate your interest in Dynavax. We are very excited about our continued progress and the strength of our position, which we believe allows us to focus on executing our long-term objectives to drive value through advancement of meaningful products to help protect the world from infectious diseases. We look forward to updating you on our progress. Operator, you may end the call.
Operator: Thank you. Ladies and gentlemen, thank you for joining us today. This concludes today’s conference call. You may now disconnect. Everyone have a wonderful day.
